NDA 212099 · Bayer Healthcare
Nubeqa
Darolutamide · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jul 30, 2019
Approved uses
4
Original approval plus efficacy supplements
Registered trials
130
30 Phase 3, 58 recruiting
FAERS reports
5,923
4,112 serious, 708 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 28, 2026.
NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. ( 1 ) NUBEQA is indicated for the treatment of adult patients with: non-metastatic castration resistant prostate cancer (nmCRPC) metastatic castration-sensitive prostate cancer (mCSPC) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.
Mechanism: Darolutamide is an androgen receptor (AR) inhibitor. Darolutamide competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. A major metabolite, ketodarolutamide, exhibited similar in vitro activity to darolutamide. In addition, darolutamide functioned as a progesterone receptor (PR) antagonist in vitro (approximately 1% activity compared to AR). Darolutamide decreased prostate cancer cell proliferation in vitro and tumor volume in mouse xenograft models of prostate cancer.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 3, 2025 Supplement 8 · Efficacy LetterLabel
- Aug 5, 2022 Supplement 2 · Efficacy · priority review LetterLabel
- Jan 7, 2021 Supplement 1 · Efficacy · priority review LetterLabel
- Jul 30, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- NUBEQA · DAROLUTAMIDE 300MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Darolutamide" as an intervention, any sponsor and status, largest first.
- A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06320067 · 3,360 participants (planned) · Start Jun 11, 2024 · Primary completion Apr 2031
Drug: Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI) and 1 more · For: Prostate Cancer Metastatic
Sites: Barnsley, United Kingdom; Cambridge, United Kingdom; Exeter, United Kingdom · 18 sites in all
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT05050084 · 2,050 participants (planned) · Start Dec 6, 2021 · Primary completion Nov 11, 2026
Drug: Bicalutamide; Buserelin and 8 more · For: Prostate Adenocarcinoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Peoria, Arizona · 576 sites in all
- Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06120491 · 1,898 participants · Start Nov 21, 2023 · Primary completion Sep 30, 2027
Drug: Saruparib; Placebo and 3 more · For: Metastatic Castration-Sensitive Prostate Cancer
Sites: Chandler, Arizona; Gilbert, Arizona; Phoenix, Arizona · 322 sites in all
- Intermittent Androgen Deprivation Therapy in the Era of AR Pathway InhibitorsPivotal-lookingRecruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT05974774 · 1,600 participants (planned) · Start May 23, 2025 · Primary completion May 23, 2035
Drug: iMAB; cMAB · For: Prostate Cancer
Sites: Copenhagen, Denmark; Caen, France; Grenoble, France · 9 sites in all
- Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT02200614 · 1,509 participants · Start Sep 12, 2014 · Primary completion Sep 3, 2018
Drug: Darolutamide (Nubeqa, BAY1841788); Placebo · For: Prostate Cancer Non-Metastatic; Castration-Resistant
Sites: Homewood, Alabama; Anchorage, Alaska; Tucson, Arizona · 404 sites in all
- Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT07751133 · 1,500 participants (planned) · Start Aug 28, 2026 · Primary completion Aug 1, 2029
Drug: Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy · For: Prostate Cancer; mHSPC; mCRPC
Sites: Huddersfield, United Kingdom; Manchester, United Kingdom; Sutton, United Kingdom · 4 sites in all
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07711002 · 1,330 participants (planned) · Start Sep 15, 2026 · Primary completion May 30, 2031
Drug: Saruparib; Enzalutamide and 2 more · For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sites: Hot Springs, Arkansas; Springdale, Arkansas; Beverly Hills, California · 210 sites in all
- Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT02799602 · 1,306 participants · Start Nov 30, 2016 · Primary completion Oct 25, 2021
Drug: BAY1841788 / darolutamide (ODM-201); Standard ADT (androgen deprivation therapy) and 2 more · For: Metastatic Hormone-sensitive Prostate Cancer
Sites: Chandler, Arizona; Tucson, Arizona; Beverly Hills, California · 322 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue881
- hot flush662
- death456
- asthenia376
- dizziness257
- prostatic specific antigen increased249
- arthralgia245
- diarrhoea242
- incorrect dose administered215
- product dose omission issue213
- dyspnoea208
- neuropathy peripheral207
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 34 |
| 2020 | 152 |
| 2021 | 204 |
| 2022 | 316 |
| 2023 | 722 |
| 2024 | 1,405 |
| 2025 | 1,987 |
| 2026 | 1,103 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nubeqa (Darolutamide)
2024 spending
$998M
Beneficiaries
11,577
78,077 claims
Per beneficiary
$86,211
$110.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $99,928,016 |
| 2021 | $223,521,256 |
| 2022 | $322,342,011 |
| 2023 | $576,350,299 |
| 2024 | $998,066,130 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Smith MR, Hussain M, Saad F, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Multicenter Study
- Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
Saad F, Vjaters E, Shore N, et al. · J Clin Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
El-Taji O, Taktak S, Jones C, et al. · JAMA Oncol 2024 · Systematic Review, Meta-Analysis
- Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Hussain M, Tombal B, Saad F, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.
Riaz IB, Naqvi SAA, He H, et al. · JAMA Oncol 2023 · Systematic Review, Network Meta-Analysis
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.